bromperidol has been researched along with Schizophrenia in 44 studies
bromperidol: bromine-substituted for chlorine in haloperidol; RN given refers to unlabeled parent cpd; structure
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia." | 9.07 | Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992) |
| " However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution." | 9.06 | [Clinical experience with bromperidol in chronic psychoses]. ( Bellomo, LE; Forconesi, N; Rosset, N; Tellarini, L, 1988) |
| "To compare the efficacy, acceptability, and tolerability of haloperidol with other first-generation antipsychotics in schizophrenia and schizophrenia-like psychosis." | 8.91 | Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. ( Dold, M; Leucht, S; Li, C; Samara, MT; Tardy, M, 2015) |
| "The relationship between Taq1 A polymorphism of dopamine D(2) receptor (DRD(2)) gene and extrapyramidal adverse effects of bromperidol and nemonapride, which are both antipsychotic drugs with selective and potent DRD(2) antagonistic property, was investigated in Japanese schizophrenic inpatients." | 6.69 | No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. ( Kaneko, S; Kondo, T; Mihara, K; Nagashima, U; Ono, S; Otani, K; Suzuki, A, 2000) |
| " The dosage calculation was made from the haloperidol doses previously received by the patients, adjusted in each particular case, with a mean of 73 mg per application (range, 50 to 200 mg)." | 6.66 | [Chronic treatment of schizophrenia with injectable bromperidol decanoate]. ( Suárez Richards, M, 1985) |
| "A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia." | 5.07 | Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992) |
| " However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution." | 5.06 | [Clinical experience with bromperidol in chronic psychoses]. ( Bellomo, LE; Forconesi, N; Rosset, N; Tellarini, L, 1988) |
| "To compare the efficacy, acceptability, and tolerability of haloperidol with other first-generation antipsychotics in schizophrenia and schizophrenia-like psychosis." | 4.91 | Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. ( Dold, M; Leucht, S; Li, C; Samara, MT; Tardy, M, 2015) |
| " He had a history of schizophrenia that had been controlled with propericiazine 10 mg and bromperidol 3 mg daily for 34 years." | 3.78 | [Severe hypotension and ventricular fibrillation during combined general and epidural anesthesia in a patient on major tranquilizers]. ( Abe, R; Fujita, K; Futsukaichi, K; Matsumoto, K; Noguchi, T, 2012) |
| " The subjects consisted of 49 acutely exacerbated inpatients with schizophrenia treated with bromperidol (30 cases, 6-18 mg/day) or nemonapride (19 cases, 18 mg/day) for 3 weeks." | 3.74 | Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia. ( Kondo, T; Mihara, K; Sakumoto, N; Suzuki, A; Yasui-Furukori, N, 2007) |
| "Plasma concentrations of bromperidol (BRP) and reduced bromperidol (RBRP) were determined in 31 patients with schizophrenia who were administered BRP for their psychiatric symptoms." | 3.70 | Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. ( Hirokane, G; Muratake, T; Shibasaki, M; Shimoda, K; Someya, T; Takahashi, S, 2000) |
| " The present study aims to investigate the relationship between the -141C Ins/Del polymorphism and extrapyramidal adverse effects of bromperidol and nemonapride, antipsychotic drugs with a selective and potent DRD2 antagonistic property, in schizophrenic inpatients." | 2.70 | No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study. ( Kaneko, S; Kondo, T; Mihara, K; Ono, S; Otani, K; Suzuki, A; Yasui, N, 2001) |
| "The relationship between Taq1 A polymorphism of dopamine D(2) receptor (DRD(2)) gene and extrapyramidal adverse effects of bromperidol and nemonapride, which are both antipsychotic drugs with selective and potent DRD(2) antagonistic property, was investigated in Japanese schizophrenic inpatients." | 2.69 | No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. ( Kaneko, S; Kondo, T; Mihara, K; Nagashima, U; Ono, S; Otani, K; Suzuki, A, 2000) |
| "Desipramine 50 mg/day was coadministered for 1 week, and blood samplings and clinical ratings were performed before and after the coadministration." | 2.68 | No interaction between desipramine and bromperidol. ( Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Suzuki, A; Yasui, N, 1996) |
| "Bromperidol is a close structural analog of haloperidol." | 2.68 | Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. ( Ikeda, K; Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Shibata, M; Suzuki, A; Yasui, N, 1997) |
| " The dosage calculation was made from the haloperidol doses previously received by the patients, adjusted in each particular case, with a mean of 73 mg per application (range, 50 to 200 mg)." | 2.66 | [Chronic treatment of schizophrenia with injectable bromperidol decanoate]. ( Suárez Richards, M, 1985) |
| "Bromperidol has a potent antipsychotic action, and some stimulating properties on activity which make it very useful when increasing patients' motivation, and resocialization is at stake." | 2.66 | [Treatment with bromperidol in schizophrenic patients]. ( Ellerman, LA, 1988) |
| " The employed dosage caused no strong sedation." | 2.64 | Double-blind comparison of bromperidol and perphenazine. ( Angst, J; Woggon, B, 1978) |
| "Constipation is a frequent adverse effect of antipsychotics and adjunctive psychotropics, which can be severe and may lead to life-threatening paralytic ileus." | 1.34 | Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report. ( Kashima, H; Suzuki, T; Uchida, H; Watanabe, K, 2007) |
| "The drug-transporting P-glycoprotein transports drugs against a concentration gradient across the blood-brain barrier back into the plasma and thereby reduces the bioavailability in the brain." | 1.33 | Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. ( Kaneda, A; Kaneko, S; Nakagami, T; Saito, M; Tateishi, T; Yasui-Furukori, N, 2006) |
| " These findings suggest that acute dystonia is affected by age factor, and that daily dosage or monitoring of drug concentration is unlikely to be a useful marker for the prediction of side-effects during bromperidol treatment." | 1.31 | The characteristics of side-effects of bromperidol in schizophrenic patients. ( Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Tanaka, O; Yasui-Furukori, N, 2002) |
| "Carbamazepine 400 mg." | 1.30 | Interaction between carbamazepine and bromperidol. ( Furukori, H; Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Suzuki, A; Yasui, N, 1997) |
| "Bromperidol treatment significantly (P < 0." | 1.30 | Prolactin response to bromperidol treatment in schizophrenic patients. ( Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Suzuki, A; Yasui, N, 1998) |
| "1." | 1.30 | Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol. ( Furukori, H; Inoue, Y; Kaneko, S; Kondo, T; Otani, K; Suzuki, A; Yasui, N, 1998) |
| "The bromperidol serum values were not correlated with the therapeutic response but, at more than 5 ng per ml, there might be a positive correlation between the bromperidol levels and clinical efficacy in the newly admitted schizophrenics." | 1.27 | Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations. ( Fujii, Y; Itoh, H; Kamisada, M; Nakajima, S; Takamiya, M; Tanoue, A; Tateyama, M, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (25.00) | 18.7374 |
| 1990's | 13 (29.55) | 18.2507 |
| 2000's | 17 (38.64) | 29.6817 |
| 2010's | 3 (6.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suzuki, H | 1 |
| Gen, K | 1 |
| Inoue, Y | 14 |
| Dold, M | 1 |
| Samara, MT | 1 |
| Li, C | 1 |
| Tardy, M | 1 |
| Leucht, S | 1 |
| Futsukaichi, K | 1 |
| Matsumoto, K | 1 |
| Fujita, K | 1 |
| Abe, R | 1 |
| Noguchi, T | 1 |
| Ohye, C | 1 |
| Shibazaki, T | 1 |
| Yasui-Furukori, N | 9 |
| Saito, M | 2 |
| Furukori, H | 9 |
| Someya, T | 2 |
| Kaneko, S | 19 |
| Tateishi, T | 2 |
| Matsumoto, M | 1 |
| Konno, T | 1 |
| Tamba, K | 1 |
| Abe, T | 1 |
| Kato, S | 1 |
| Kajii, E | 1 |
| Perquin, LN | 1 |
| Nakagami, T | 1 |
| Kaneda, A | 1 |
| Sakumoto, N | 1 |
| Kondo, T | 17 |
| Mihara, K | 14 |
| Suzuki, A | 15 |
| Suzuki, T | 1 |
| Uchida, H | 1 |
| Watanabe, K | 1 |
| Kashima, H | 1 |
| Brannen, JO | 2 |
| McEvoy, JP | 2 |
| Wilson, WH | 2 |
| Petrie, WM | 1 |
| Ban, TA | 2 |
| Berney, SA | 1 |
| Schaffer, JD | 1 |
| Fujii, Y | 1 |
| Tateyama, M | 1 |
| Kamisada, M | 1 |
| Tanoue, A | 1 |
| Takamiya, M | 1 |
| Nakajima, S | 1 |
| Itoh, H | 2 |
| Tischio, J | 1 |
| Hetyei, N | 1 |
| Patrick, J | 1 |
| Berney, S | 1 |
| Seno, H | 1 |
| Kumazawa, T | 1 |
| Ishii, A | 1 |
| Sato, K | 1 |
| Suzuki, O | 1 |
| Suzuki, E | 1 |
| Kanba, S | 1 |
| Koshikawa, H | 1 |
| Nibuya, M | 1 |
| Yagi, G | 1 |
| Asai, M | 1 |
| Otani, K | 17 |
| Ishida, M | 9 |
| Yasui, N | 10 |
| Shibata, M | 2 |
| Ikeda, K | 2 |
| Tokinaga, N | 2 |
| Hayashi, K | 1 |
| Nagashima, U | 2 |
| Muratake, T | 1 |
| Hirokane, G | 1 |
| Shibasaki, M | 1 |
| Shimoda, K | 1 |
| Takahashi, S | 1 |
| Ono, S | 3 |
| Inoue, M | 1 |
| Tanaka, O | 1 |
| Yagdiran, O | 1 |
| Haasen, C | 1 |
| Nika, E | 1 |
| Krausz, M | 1 |
| Naber, D | 1 |
| Woggon, B | 1 |
| Angst, J | 1 |
| Pöldinger, W | 1 |
| Bures, E | 1 |
| Haage, H | 1 |
| McLaren, S | 1 |
| Cookson, JC | 1 |
| Silverstone, T | 1 |
| Suárez Richards, M | 1 |
| Ellerman, LA | 1 |
| Bellomo, LE | 1 |
| Rosset, N | 1 |
| Tellarini, L | 1 |
| Forconesi, N | 1 |
| Rapisarda, V | 1 |
| Bonomo, V | 1 |
| Parisi, R | 1 |
1 review available for bromperidol and Schizophrenia
| Article | Year |
|---|---|
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
Topics: Administration, Oral; Antipsychotic Agents; Haloperidol; Humans; Loxapine; Psychotic Disorders; Rand | 2015 |
17 trials available for bromperidol and Schizophrenia
| Article | Year |
|---|---|
Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Autoanalysis; Cross Reactions; Drug Monitoring | 2004 |
A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Evaluation; Haloperidol; Humans; Psychiatric Status | 1981 |
Bromperidol maintenance in schizophrenia.
Topics: Double-Blind Method; Haloperidol; Humans; Psychiatric Status Rating Scales; Schizophrenia; Schizophr | 1982 |
No interaction between desipramine and bromperidol.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 1996 |
No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite.
Topics: Adult; Biperiden; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia; | 1997 |
Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.
Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Haloperidol; Humans; M | 1997 |
Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.
Topics: Adolescent; Adult; Aged; Aging; Anti-Anxiety Agents; Antipsychotic Agents; Biotransformation; Cytoch | 1998 |
No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study.
Topics: Acute Disease; Alleles; Antipsychotic Agents; Benzamides; Dopamine Antagonists; Dopamine D2 Receptor | 2000 |
No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study.
Topics: Adult; Benzamides; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Polymorphism, Genetic; R | 2001 |
Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.
Topics: Adult; Antipsychotic Agents; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Polymorphism, | 2001 |
Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Patient Compliance; Psy | 2002 |
Double-blind comparison of bromperidol and perphenazine.
Topics: Adult; Aged; Behavior; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; M | 1978 |
Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
Topics: Adult; Aged; Chronic Disease; Depression; Double-Blind Method; Female; Fluphenazine; Haloperidol; Hu | 1992 |
[Chronic treatment of schizophrenia with injectable bromperidol decanoate].
Topics: Adult; Brief Psychiatric Rating Scale; Chronic Disease; Clinical Trials as Topic; Female; Haloperido | 1985 |
[Treatment with bromperidol in schizophrenic patients].
Topics: Brief Psychiatric Rating Scale; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Schizop | 1988 |
[Clinical experience with bromperidol in chronic psychoses].
Topics: Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Inp | 1988 |
A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
Topics: Clinical Trials as Topic; Double-Blind Method; Haloperidol; Humans; Schizophrenia | 1985 |
26 other studies available for bromperidol and Schizophrenia
| Article | Year |
|---|---|
Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof.
Topics: Adult; Algorithms; Antipsychotic Agents; Biotransformation; Brain; Chlorpromazine; Diagnostic and St | 2013 |
[Severe hypotension and ventricular fibrillation during combined general and epidural anesthesia in a patient on major tranquilizers].
Topics: Anesthesia, Epidural; Anesthesia, General; Antipsychotic Agents; Haloperidol; Humans; Hypotension; I | 2012 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulatio | 2001 |
Two cases of deep vein thrombosis associated with antipsychotic drug use.
Topics: Aged; Antipsychotic Agents; Chlorpromazine; Depressive Disorder, Major; Dose-Response Relationship, | 2004 |
Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Clopenthixol; Female; Haloperidol; Humans; Imid | 2005 |
Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
Topics: Adult; Antipsychotic Agents; Female; Genes, MDR; Genotype; Haloperidol; Humans; Male; Middle Aged; P | 2006 |
Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Dopamine Antagonists; Dose-Response Relationship, Drug; Fem | 2007 |
Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report.
Topics: Aged; Antipsychotic Agents; Constipation; Dementia; Dose-Response Relationship, Drug; Drug Therapy, | 2007 |
Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations.
Topics: Adult; Biperiden; Brief Psychiatric Rating Scale; Drug Therapy, Combination; Dyskinesia, Drug-Induce | 1984 |
Bromperidol radioimmunoassay: human plasma levels.
Topics: Antibody Specificity; Biological Availability; Biotransformation; Cross Reactions; Haloperidol; Huma | 1984 |
Determination of some butyrophenones in body fluids by gas chromatography with surface ionization detection.
Topics: Butyrophenones; Chromatography, Gas; Haloperidol; Humans; Schizophrenia; Sensitivity and Specificity | 1993 |
Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Topics: Adult; Aged; Antipsychotic Agents; Depression; Dopamine D2 Receptor Antagonists; Dose-Response Relat | 1996 |
Possible interaction between cisapride and bromperidol.
Topics: Adult; Cisapride; Drug Interactions; Haloperidol; Humans; Male; Piperidines; Schizophrenia; Sympatho | 1997 |
Interaction between carbamazepine and bromperidol.
Topics: Adult; Analgesics, Non-Narcotic; Antipsychotic Agents; Carbamazepine; Chromatography, High Pressure | 1997 |
Prolactin response to bromperidol treatment in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Schizophreni | 1998 |
[Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Cytochrome P-450 CYP3A; Cytochrome P-450 | 1998 |
Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
Topics: Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1998 |
Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients.
Topics: Adult; Aged; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme I | 1999 |
Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biotransformation; Dose-Response Relationship, Drug; | 2000 |
Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.
Topics: Adult; Alleles; Deoxyribonucleases, Type II Site-Specific; Dopamine Antagonists; Female; Genotype; H | 2001 |
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Anxiety; Benzamides; Depression; Dopamine Antagonists; Female; Haloperi | 2001 |
The characteristics of side-effects of bromperidol in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dystonia; Female; Haloperidol; Humans; Hypokinesia; Male; Schizophrenia | 2002 |
Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Schizophrenia; Statistics, Nonpara | 2002 |
Switching to amisulpride due to hepatic complications.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Flupenthixol; Halo | 2002 |
Clinical study with bromperidol, a new butyrophenone derivative.
Topics: Adult; Bromine; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1977 |
Long-acting therapy of schizophrenia.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzodiazepines; Biofeedback, Psychology; Bromocriptine; Dy | 1985 |